[#바이오스펙테이터](?q=%23%EB%B0%94%EC%9D%B4%EC%98%A4%EC%8A%A4%ED%8E%99%ED%85%8C%EC%9D%B4%ED%84%B0) [#전일](?q=%23%EC%A0%84%EC%9D%BC)(10/7, WED) [#전체기사](?q=%23%EC%A0%84%EC%B2%B4%EA%B8%B0%EC%82%AC)

 릴리, '분자게이트 저분자' 발굴 확대 "8.7억弗 딜"
[https://www.biospectator.com/news/view/29999](https://www.biospectator.com/news/view/29999)

 릴리, '비공유 BTK' CLL∙SLL 1차 "FDA 확대 승인" 
[https://www.biospectator.com/news/view/30000](https://www.biospectator.com/news/view/30000)

 롯데바이오로직스, 알보텍과 생산수주 계약 "체결"
[https://www.biospectator.com/news/view/30014](https://www.biospectator.com/news/view/30014)

 HLB, ‘리라푸그라티닙’ 유럽 허가 "본심사 착수"
[https://www.biospectator.com/news/view/30019](https://www.biospectator.com/news/view/30019)

 셀트리온, ‘앱토즈마’ 소아 코로나19 "FDA 승인확대"
[https://www.biospectator.com/news/view/30022](https://www.biospectator.com/news/view/30022)

 로슈, 알렉토와 파킨슨병 'BBB ERT' 12.7억弗 딜
[https://www.biospectator.com/news/view/29995](https://www.biospectator.com/news/view/29995)

 젠맙, 'FRα ADC' 백금저항성 난소암 1/2상 “cORR 45.9%"
[https://www.biospectator.com/news/view/29993](https://www.biospectator.com/news/view/29993)

 지아이이노베이션, 마루호 'IgE Trap' 2상 "이달 첫 투약" 
[https://www.biospectator.com/news/view/30023](https://www.biospectator.com/news/view/30023)

 CSL, 알렌티스와 ‘CLDN1 항체’ 공동개발 “15.5억弗 딜”
[https://www.biospectator.com/news/view/30004](https://www.biospectator.com/news/view/30004)

 아리벤트, '뇌투과성' EGFR 저해제 폐암 3상 "실패" 
[https://www.biospectator.com/news/view/30021](https://www.biospectator.com/news/view/30021)

 GC셀, 'CD5 CAR-NK' 림프종 국내1b상 “첫 환자투약”
[https://www.biospectator.com/news/view/30020](https://www.biospectator.com/news/view/30020)

 Vetter, 고객수요 대응 위해 “충전라인 10개 추가 구축”
[https://www.biospectator.com/news/view/30010](https://www.biospectator.com/news/view/30010)

 삼성바이오, 바이오재팬서 'CDMO·ADC 공정' 세미나
[https://www.biospectator.com/news/view/30024](https://www.biospectator.com/news/view/30024)

 펩트론, 릴리와 'SmartDepot' 플랫폼 기술평가 "기간종료"
[https://www.biospectator.com/news/view/30027](https://www.biospectator.com/news/view/30027)

 "첫 국산 GLP-1 비만약", 한미약품 '에페' 국내 허가
[https://www.biospectator.com/news/view/30029](https://www.biospectator.com/news/view/30029)

 샤페론, '누겔' 아토피 2b상 활성약·위약 기재 "오류확인"
[https://www.biospectator.com/news/view/30026](https://www.biospectator.com/news/view/30026)

[#바이오스펙테이터](?q=%23%EB%B0%94%EC%9D%B4%EC%98%A4%EC%8A%A4%ED%8E%99%ED%85%8C%EC%9D%B4%ED%84%B0) [#전일](?q=%23%EC%A0%84%EC%9D%BC)(10/7, WED) [#전체기사](?q=%23%EC%A0%84%EC%B2%B4%EA%B8%B0%EC%82%AC)